CA3236215A1 - Nant covid vaccine cross reactivity - Google Patents
Nant covid vaccine cross reactivity Download PDFInfo
- Publication number
- CA3236215A1 CA3236215A1 CA3236215A CA3236215A CA3236215A1 CA 3236215 A1 CA3236215 A1 CA 3236215A1 CA 3236215 A CA3236215 A CA 3236215A CA 3236215 A CA3236215 A CA 3236215A CA 3236215 A1 CA3236215 A1 CA 3236215A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- sars
- vaccine
- recombinant
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163284203P | 2021-11-30 | 2021-11-30 | |
| US63/284,203 | 2021-11-30 | ||
| PCT/US2022/080561 WO2023102375A1 (en) | 2021-11-30 | 2022-11-29 | Nant covid vaccine cross reactivity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3236215A1 true CA3236215A1 (en) | 2023-06-08 |
Family
ID=86613140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3236215A Pending CA3236215A1 (en) | 2021-11-30 | 2022-11-29 | Nant covid vaccine cross reactivity |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11911459B2 (https=) |
| EP (1) | EP4440614A4 (https=) |
| JP (1) | JP2024543954A (https=) |
| KR (1) | KR20240113521A (https=) |
| CN (1) | CN118338912A (https=) |
| AU (1) | AU2022400924A1 (https=) |
| CA (1) | CA3236215A1 (https=) |
| WO (1) | WO2023102375A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7692925B2 (ja) * | 2020-03-11 | 2025-06-16 | ナントセル，インコーポレイテッド | Ｃｏｖｉｄ－１９の治療及びその方法 |
| EP4118225A1 (en) * | 2020-03-13 | 2023-01-18 | The Johns Hopkins University | Exosomal nucleic acid vaccine modularly configured to harness multiple antigen presentation mechanisms |
| CN115666634A (zh) * | 2020-03-27 | 2023-01-31 | 瑞典疫苗制药有限公司 | 用于治疗和预防冠状病毒的组合物和方法 |
| WO2021255270A1 (en) * | 2020-06-19 | 2021-12-23 | Ziphius Vaccines | Self-amplifying sars-cov-2 rna vaccine |
-
2022
- 2022-11-29 KR KR1020247020418A patent/KR20240113521A/ko active Pending
- 2022-11-29 WO PCT/US2022/080561 patent/WO2023102375A1/en not_active Ceased
- 2022-11-29 JP JP2024532354A patent/JP2024543954A/ja active Pending
- 2022-11-29 AU AU2022400924A patent/AU2022400924A1/en active Pending
- 2022-11-29 EP EP22902334.6A patent/EP4440614A4/en active Pending
- 2022-11-29 CN CN202280079239.5A patent/CN118338912A/zh active Pending
- 2022-11-29 CA CA3236215A patent/CA3236215A1/en active Pending
- 2022-11-30 US US18/060,513 patent/US11911459B2/en active Active
-
2023
- 2023-12-07 US US18/533,042 patent/US12016916B2/en active Active
-
2024
- 2024-03-28 US US18/620,192 patent/US12168052B2/en active Active
- 2024-09-11 US US18/882,219 patent/US20240424088A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12016916B2 (en) | 2024-06-25 |
| EP4440614A1 (en) | 2024-10-09 |
| JP2024543954A (ja) | 2024-11-26 |
| US11911459B2 (en) | 2024-02-27 |
| KR20240113521A (ko) | 2024-07-22 |
| US20240424088A1 (en) | 2024-12-26 |
| WO2023102375A1 (en) | 2023-06-08 |
| US20230190921A1 (en) | 2023-06-22 |
| EP4440614A4 (en) | 2025-12-17 |
| US20240226282A1 (en) | 2024-07-11 |
| US12168052B2 (en) | 2024-12-17 |
| CN118338912A (zh) | 2024-07-12 |
| AU2022400924A1 (en) | 2024-05-02 |
| US20240108717A1 (en) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102945692B1 (ko) | 아프리카 돼지 열병 바이러스 백신 | |
| EA016648B1 (ru) | Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии | |
| JP2003520597A (ja) | 組換えフラビウイルスおよびその使用方法 | |
| JP6917303B2 (ja) | 人工多抗原融合タンパク質およびその製造と使用 | |
| EP4174183A1 (en) | Fusion gene, recombinant novel coronavirus high-efficiency immune dna vaccine, construction method therefor and use thereof | |
| US20230310585A1 (en) | Vaccine for viral pathogens | |
| US20230192777A1 (en) | Epitopic vaccine for african swine fever virus | |
| KR101845571B1 (ko) | 전통적 돼지열에 대한 마커 백신 | |
| US12016916B2 (en) | Nant COVID vaccine cross reactivity | |
| JPH04500066A (ja) | ポリペプチドの百日咳トキシンのワクチン | |
| EA012436B1 (ru) | Композиции для иммунизации против микобактерий | |
| US20060263389A1 (en) | Methods and compositions to enhance immune responses via recall antigens | |
| CN110382518B (zh) | 用于血清型a型口蹄疫病毒的嵌合疫苗 | |
| US20250332246A1 (en) | Enhanced expression via autotransporters | |
| US20260053900A1 (en) | Use of virus-like particles in vaccination | |
| KR20110060865A (ko) | 리슈마니아증 및 결핵에 대한 백신 개발을 위한 ｄｎａ 키메라의 작제 | |
| US20240092840A1 (en) | Vaccine formulation comprising recombinant overlapping peptides and native proteins | |
| TW201930346A (zh) | 用於ＩｇＥ介導過敏性疾病治療之靶向膜鑲嵌型ＩｇＥ的胜肽免疫原及其劑型 | |
| CN100368436C (zh) | 人绒毛膜促性腺激素重组多表位嵌合肽cp22抗原的分子设计及其制备方法 | |
| CN117801119A (zh) | T细胞表位疫苗及其设计方法 | |
| WO2025137448A1 (en) | T cell-based sars-cov-2 vaccine | |
| CN121226564A (zh) | 一种SARS-CoV-2刺突蛋白抗原表位混合多肽及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241010 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241119 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241119 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241119 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251117 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251117 |